Calpain inhibitors - A review of the recent patent literature

IDrugs

Volumn 5, Issue 6, 2002, Pages 568-576

  DePetrillo, Paolo B ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; AK 275; AK 295; AURINTRICARBOXYLIC ACID; BENZAMIDOALDEHYDE DERIVATIVE; CALCIUM; CALPAIN; CALPASTAT; CALPASTATIN; CARBOXIMIDE DERIVATIVE; CEP 4143; CLAVAM 3 CARBOXIMIDE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; INDOLECARBOXAMIDE DERIVATIVE; MDL 104903; N ACETYLLEUCYLLEUCYLNORLEUCINE; PD 150606; PD 151746; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC INHIBITOR; PEPTIDYL 2 AMINO 1 HYDROXYALKANESULFONIC ACID DERIVATIVE; PEPTIDYL INHIBITOR; PIPERAZINE DERIVATIVE; PROTEINASE INHIBITOR; QUINOLINECARBOXIMIDE DERIVATIVE; RITONAVIR; SJA 5011; SJA 6017; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CELL DEATH; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART INFARCTION; HUMAN; IC 50; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATENT; PROTEIN DEGRADATION; REVIEW; SIDE EFFECT; SPINAL CORD INJURY; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION;

EID: 0141783985     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Guroff G: A neutral calcium-activated proteinase from the soluble fraction of rat brain. J Biol Chem (1964) 239:149-155.
2. Huang Y, Wang KK: The calpain family and human disease. Trends Mol Med (2001) 7:355-362.
3. Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H: The HUGO Gene Nomenclature Committee (HGNC). Hum Genet (2001) 109:678-680.
4. Dear N, Matena K, Vingron M, Boehm T: A new sub-family of vertebrate calpains lacking a calmodulin-like domain: Implications for calpain regulation and evolution. Genomics (1997) 48:175-184.
5. Rogers S, Wells R, Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science (1986) 234:364-368.
6. Rechsteiner M, Rogers SW: PEST sequences and regulation by proteolysis. Trends Biochem Sci (1996) 21:267-271.
7. Carillo S, Pariat M, Steff A, Jariel-Encontre I, Poulat F, Berta P, Piechaczyk M: PEST motifs are not required for rapid calpain-mediated proteolysis of c-fos protein. Biochem J (1996) 313(Pt 1):245-251.
8. Del Cerro S, Arai A, Kessler M, Bahr BA, Vanderklish P, Rivera S, Lynch G: Stimulation of NMDA receptors activates calpain in cultured hippocampal slices. Neurosci Lett (1994) 167:149-152.
9. Bi X, Rong Y, Chen J, Dang S, Wang Z, Baudry M: Calpain-mediated regulation of NMDA receptor structure and function. Brain Res (1998) 790:245-253.
10. Hell JW, Westenbroek RE, Breeze LJ, Wang KK, Chavkin C, Catterall WA: N-methyl-D-aspartate receptor-induced proteolytic conversion of postsynaptic class C L-type calcium channels in hippocampal neurons. Proc Natl Acad Sci USA (1996) 93:3362-3367.
11. Bi X, Tocco G, Baudry M: Calpain-mediated regulation of AMPA receptors in adult rat brain. Neuroreport (1994) 6:61-64.
12. Hewitt KE, Lesiuk HJ, Tauskela JS, Morley P, Durkin JP: Selective coupling of μ-calpain activation with the NMDA receptor is independent of translocation and autolysis in primary cortical neurons. J Neurosci Res (1998) 54:223-232.
13. Bi X, Chen J, Baudry M: Developmental changes in calpain activity, GluR1 receptors and in the effect of kainic acid treatment in rat brain. Neuroscience (1997) 81:1123-1135.
14. Choi DW: Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci (1994) 747:162-171.
15. Lankiewicz S, Luetjens C, Truc Bui N, Krohn AJ, Poppe M, Cole GM, Saido TC, Prehn JH: Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death. J Biol Chem (2000) 275:17064-17071.
16. Rami A, Ferger D, Krieglstein J: Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci Res (1997) 27:93-97.
17. Kishimoto A, Kajikawa N, Shiota M, Nishizuka Y: Proteolytic activation of calcium-activated, phospholipid-dependent protein kinase by calcium-dependent neutral protease. J Biol Chem (1983) 258:1156-1164.
18. Shea TB, Beermann ML, Griffin WR, Leli U: Degradation of protein kinase Cα and its free catalytic subunit, protein kinase M, in intact human neuroblastoma cells and under cell-free conditions. Evidence that PKM is degraded by mM calpain-mediated proteolysis at a faster rate than PKC. FEBS Lett (1994) 350:223-229.
19. 2+-independent form of kinase C in long-term potentiation. Biochem Biophys Res Commun (1992) 189:1515-1520.
20. 2+-induced persistent protein kinase C activation in rat hippocampal homogenates. Second Messengers Phosphoproteins (1994) 14:109-126.
21. Wu Y, Wang L: The effects of antiepileptic drugs on spatial learning and hippocampal protein kinase Cγ in immature rats. Brain Develop (2002) 24:82-87.
22. Harada K, Maekawa T, Abu Shama KM, Yamashima T, Yoshida K: Translocation and down-regulation of protein kinase Cα, -β, and -γ isoforms during ischemia-reperfusion in rat brain. J Neurochem (1999) 72:2556-2564.
23. Yoshida K, Hirata T, Akita Y, Mizukami Y, Yamaguchi K, Sorimachi Y, Ishihara T, Kawashiama S: Translocation of protein kinase Cα, δ and ε isoforms in ischemic rat heart. Biochim Biophys Acta (1996) 1317:36-44.
24. Urthaler F, Wolkowicz PE, Digerness SB, Harris KD, Walker AA: MDL-28170, a membrane-permeant calpain inhibitor, attenuates stunning and PKCε proteolysis in reperfused ferret hearts. Cardiovasc Res (1997) 35:60-67.
25. Liu ZQ, Kunimatsu M, Yang JP, Ozaki Y, Sasaki M, Okamoto T: Proteolytic processing of nuclear factor κB by calpain in vitro. FEBS Lett (1996) 385:109-113.
26. Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR: Tumor necrosis factor-α-inducible IκBα proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-κB activation. J Biol Chem (1999) 274:787-794.
27. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C: Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell (1995) 81:27-40.
28. Baghdiguian S, Richard I, Martin M, Coopman P, Beckmann JS, Mangeat P, Lefranc G: Pathophysiology of limb girdle muscular dystrophy type 2A: Hypothesis and new insights into the IκBα/NF-κB survival pathway in skeletal muscle. J Mol Med (2001) 79:254-261.
29. Christman JW, Lancaster LH, Blackwell TS: Nuclear factor κB: A pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med (1998) 24:1131-1138.
30. Ruetten H, Thiemermann C: Effect of calpain inhibitor I, an inhibitor of the proteolysis of IκB, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol (1997) 121:695-704.
31. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB: Regulation of cyclin D1 by calpain protease. J Biol Chem (1997) 272:28479-28484.
32. Jang JS, Lee SJ, Choi YH, Nguyen PM, Lee J, Hwang SG, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB: Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease. Oncogene (1999) 18:1789-1796.
33. Kubbutat MH, Vousden KH: Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol Cell Biol (1997) 17:460-468.
34. Selliah N, Brooks WH, Roszman TL: Proteolytic cleavage of α-actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody. J Immunol (1996) 156:3215-3221.
35. Wojcikiewicz RJ, Oberdorf JA: Degradation of inositol 1,4,5-trisphosphate receptors during cell stimulation is a specific process mediated by cysteine protease activity. J Biol Chem (1996) 271:16652-16655.
36. Smith LK, Rice KM, Garner CW: The insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium-dependent thiol protease. Mol Cell Endocrinol (1996) 122:81-92.
37. Noguchi M, Sarin A, Aman MJ, Nakajima H, Shores EW, Henkart PA, Leonard WJ: Functional cleavage of the common cytokine receptor γ-chain (γc) by calpain. Proc Natl Acad Sci USA (1997) 94:11534-11539.
38. Fox JE: Cytoskeletal proteins and platelet signaling. Thromb Haemost (2001) 86:198-213.
39. Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A, Chishti AH: Disruption of the mouse μ-calpain gene reveals an essential role in platelet function. Mol Cell Biol 2001 21:2213-2220.
40. Bhattacharya J, Dey R, Datta SC: Calcium dependent thiol protease caldonopain and its specific endogenous inhibitor in Leishmania donovani. Mol Cell Biochem (1993) 126:9-16.
41. Olaya P, Wasserman M: Effect of calpain inhibitors on the invasion of human erythrocytes by the parasite Plasmodium falciparum. Biochim Biophys Acta (1991) 1096:217-221.
42. Hertz-Fowler C, Ersfeld K, Gull K: CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. Mol Biochem Parasitol (2001) 116:25-34.
43. Que X, Reed SL: Cysteine proteinases and the pathogenesis of amebiasis. Clin Microbiol Rev (2000) 13:196-206.
44. Donkor IO: A survey of calpain inhibitors. Curr Med Chem (2000) 7:1171-1188. Comprehensive review of the structure-activity relationship of calpain inhibitors.
45. Angelastro MR, Marquart AL, Mehdi S, Koehl JR, Vaz RJ, Bey P, Peet NP: The synthesis of ketomethylene pseudopeptide analogues of dipeptide aldehyde inhibitors of calpain. Bioorg Med Chem Lett (1999) 9:139-140.
46. 3 are not required for substrate binding.
47. 2-achiral,P′-extended α-ketoamide inhibitors of calpain I. Bioorg Med Chem Lett (1999) 9:2371-2374.
48. Wang KK, Nath R, Posner A, Raser KJ, Buroker-Kilgore M, Hajimohammadreza I, Probert A W Jr, Marcoux FW, Ye Q, Talkano E, Hatanaka M, Maki M, Caner H, Collins JL, Fergus A, Lee KS, Lunney EA, Hays SJ, Yuen P: An α-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA (1996) 93:6687-6692. First allosteric inhibitor of calpain shown to bind to calcium-binding domain.
49. Robert-Lewis JM, Marcy VR, Zhao Y, Vaught JL, Siman R, Lewis ME: Aurintricarboxylic acid protects hippocampal neurons from NMDA-and ischemia-induced toxicity in vivo. J Neurochem (1993) 61:378-381. One of the first reports suggesting potent neuroprotective effects of calpain inhibitors against ischemic brain injury.
50. Posner A, Raser KJ, Hajimohammadreza I, Yuen PW, Wang KK: Aurintricarboxylic acid is an inhibitor of μ- and m-calpain. Biochem Molecular Biol Int (1995) 36:291-299.
51. Graybill TL, Dolle RE, Osito IK, Schmidt SJ, Gregory, JS, Harris AL, Miller MS: Inhibition of human erythrocyte calpain I by novel quinolinecarboxamides. Bioorg Med Chem Lett (1995) 5:387-392.
52. Wan W, DePetrillo PB: Ritonavir inhibition of calcium-activated neutral proteases. Biochem Pharmacol (2002) 63:1481-1484.
53. Croce K, Flaumenhaft R, Rivers M, Furie B, Furie BC, Herman IM, Potter DA: Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem (1999) 274:36321-36327.
54. Josef KA, Kauer FW, Bihovsky R: Potent peptide α-ketohydroxamate inhibitors of recombinant human calpain I. Bioorg Med Chem Lett (2001) 11:2615-2617.
55. 2 substituents are compatible with potent calpain inhibition.
56. 2 position.
57. Peet NP, Kim HO, Marquart AL, Algelastro MR, Nieduzak TR, White JN, Friedrich D, Flynn GA, Webster ME, Vaz RJ, Linnik MD, Koehl JR, Mehdi S, Bey P, Emary B, Hwang KK: Hydroxyoxazolidines as α-aminoacetaldehye equivalents: Novel inhibitors of calpain. Bioorg Med Chem Lett (1999) 9:2365-2370.
58. Ando R, Sakaki T, Morinaka Y, Takahashi C, Tamao Y, Yoshii N, Katayama S, Saito K, Tokuyama H, Isaka M, Nakamura E: Cyclopropenone-containing cysteine proteinase inhibitors. Synthesis and enzyme inhibitory activities. Bioorg Med Chem (1999) 7:571-579.
59. Inoue J, Yoshida Y, Nakamura M, Cui YS, Nagao Y: Syntheses and SH-enzyme inhibitory activities of new epoxysuccinic acid piperazine derivatives against μ-calpain and cathepsin B. Drug Des Discov (1999) 16:165-169.
60. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI, Rafols JA, Krause GS: Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. J Neurol Sci (2000) 179:1-33.
61. Bartus RT, Baker KL, Heiser AD, Sawyer SD, Dean RL, Elliott PJ, Straub JA: Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab (1994) 14:537-544.
62. Bartus RT, Hayward NJ, Elliott PJ, Sawyer SD, Baker KL, Dean RL, Akiyama A, Straub JA, Harbeson SL, Li Z: Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. Stroke (1994) 25:2265-2270.
63. Saatman KE, Murai H, Bartus RT, Smith DH, Hayward NJ, Perri BR, McIntosh TK: Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci USA (1996) 93:3428-3433.
64. James T, Matzelle D, Bartus R, Hogan EL, Banik NL: New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro. J Neurosci Res (1998) 51:218-222.
65. Palmer JT, Rasnick D, Klaus JL, Bromme D: Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem (1995) 38:3193-3196.
66. Biroc SL, Gay S, Hummel K, Magill C, Palmer JT, Spencer DR, Sa S, Klaus JL, Michel BA, Rasnick D, Gay RE: Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis Rheum (2001) 44:703-711.
67. Schumacher PA, Siman RG, Fehlings MG: Pretreatment with calpain inhibitor CEP- 4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. J Neurochem (2000) 74:1646-1655.
68. Li PA, Howlett W, He QP, Miyashita H, Siddiqui M, Shuaib A: Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett (1998) 247:17-20.
69. Brana C, Benham CD, Sundstrom LE: Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. Eur J Neurosci (1999) 11:2375-2384.
70. Lubisch W, Hoffmann HP, Treiber HJ, Moller A: Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors. Bioorg Med Chem Lett (2000) 10:2187-2191.
71. Liu X, Rainey JJ, Harriman JF, Schnellmann RG: Calpains mediate acute renal cell death: Role of autolysis and translocation. Am J Physiology - Renal Physiology (2001) 281:F728-F738.
72. Kupina NC, Nath R, Bernath EE, Inoue J, Mitsuyoshi A, Yuen PW, Wang KK, Hall ED: The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma (2001) 18:1229-1240.
73. Mathur P, Gupta SK, Wegener AR, Breipohl W, Ahrend MH, Sharma YD, Gupta YK, Vajpayee RB: Comparison of various calpain inhibitors in reduction of light scattering, protein precipitation and nuclear cataract in vitro. Curr Eye Res (2000) 21:926-933.
74. Toda G, Matsushita S, Kuramoto K, Oda S, Ezaki H, Hattori A, Kawashima S: Calcium- activated neutral protease inhibitor (E-64c) and reperfusion for experimental myocardial infarction. Jpn Heart J (1989) 30:375-386. First study suggesting utility of calpain inhibitors in reducing myocardial infarct size.
75. Merrell Dow Pharmaceuticals Inc (Bey P, Mehdi S, Angelastro M): Novel peptidase inhibitors. EP-00363284 (1990).
76. Cephalon Inc (Chatterjee S): Ketomethylene group-containing cysteine and serine protease inhibitors. WO-09710231 (1997).
77. Cephalon Inc (Chatterjee S): Ketomethylene group-containing cysteine and serine protease inhibitors. US-05723580 (1998).
78. Cephalon Inc (Chatterjee S): Ketomethylene group-containing cysteine and serine protease inhibitors. US-05827877 (1998).
79. Cephalon Inc (Chatterjee S): Ketomethylene group-containing cysteine and serine protease inhibitors. US-06034095 (2000).
80. Cephalon Inc (Chatterjee S): Ketomethylene group-containing cysteine and serine protease inhibitors. US-06329377 (2001).
81. Cephalon Inc (Bihovsky R, Wells GJ, Tao M): Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors. US-05952328 (1999).
82. Cephalon Inc (Chatterjee S, Mallamo JP, Bihovsky R, Wells GJ): Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors. US-06150378 (2000).
83. Warner-Lambert Co (Wang KK, Yuen PW): α-Mercaptoacrylic acid derivatives having calpain inhibitory activity. US-05554767 (1996).
84. Smithkline Beecham Corp (Gallagher G, Gleason JG, Kingsbury WD, Pendrak I): 3-Substituted clavams for calpain inhibition. WO-09837084 (1998).
85. Sterling Winthrop Inc (Dolle RE, Graybill TL, Osifo IK, Harris AL, Miller MS, Gregory JS): Quinolone carboxamide calpain inhibitors. US-05622967 (1997).
86. US Department of Health and Human Services (DePetrillo PB, Wan W): Methods of and compounds for inhibiting calpains. WO-00182919 (2001).
87. New England Medical Center Hospitals Inc (Potter DA, Skolnik P): Cell-permeable protein inhibitors of calpain. US-06294518 (2001).
88. BASF Aktiengesellschaft (Lubisch W, Moller A, Treiber HJ): Benzamidoaldehydes and their use as cysteine protease inhibitors. US-06251917 (2001).
89. Cephalon Inc (Tao M, Bihovsky R): Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors. US-06348448 (2002).
90. Cephalon Inc (Chatterjee S, Mallamo JP, Bihovsky R, Wells GJ): Peptide-containing α-ketoamide cysteine and serine protease inhibitors. US-06288231 (2001).
91. 2 position, methods of making same, and methods of using same. US-05852007 (1998).
92. SmithKline Beecham Corp (Daines RA, Sham KKC): Indolecarboxamides, pharmaceutical compositions and methods of inhibiting calpain. US-06214856 (2001).
93. SmithKline Beecham Corp & Cephalon Inc (Daines RA, Kingsbury WD, Pendrak I, Mallamo JP): Quinolone- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain. US-06100267 (2000).
94. Hoechst Marion Roussel Inc (Peet NP, Mehdi S, Linnik MD, Angelastro MR, Kim HO): Substituted oxazolidine calpain and/or cathepsin B inhibitors. US-05691368 (1997).
95. Mitsubishi Kasei Corp (Ando R, Morinaka Y, Takahashi C, Tamao Y, Tobe A): Cyclopropenone derivatives. US-05416117 (1995).
96. Senju Pharmaceutical Co Ltd (Inoue J, Yoshida Y, Cui YS, Azuma M): Piperazine derivatives and use as cysteine inhibitors. US-05935959 (1999).
97. Georgia Tech Research Corp (Powers JC): Tripeptide α-ketoamides. US-06235929 (2001).
98. Georgia Tech Research Corp (Powers JC): Peptide ketoamides. US-05650508 (1997).
99. Harbeson SL, Straub JA: Optically pure calpain inhibitor compounds. US-05541290 (1996).
100. Axys Pharmaceuticals Inc (Palmer JT, Rasnick D, Klaus JL): Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups. US-06287840 (2001).
101. BASF Aktiengesellschaft (Lubisch W, Moller A, Treiber HJ): Ketobenzamides as calpain inhibitors. US-06103720 (2000).
102. Senju Pharmaceutical Co Ltd (Azuma M, Yoshida Y, Sakamoto Y, Inoue J): Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment. US-06342531 (2002).